FR21C1028I1 - Anticorps monoclonaux humains contre le cd20 pour le traitement de la sclérose en plaques - Google Patents

Anticorps monoclonaux humains contre le cd20 pour le traitement de la sclérose en plaques

Info

Publication number
FR21C1028I1
FR21C1028I1 FR21C1028C FR21C1028C FR21C1028I1 FR 21C1028 I1 FR21C1028 I1 FR 21C1028I1 FR 21C1028 C FR21C1028 C FR 21C1028C FR 21C1028 C FR21C1028 C FR 21C1028C FR 21C1028 I1 FR21C1028 I1 FR 21C1028I1
Authority
FR
France
Prior art keywords
human
monoclonal antibodies
antibodies
human monoclonal
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1028C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32110219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1028(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genmab AS filed Critical Genmab AS
Publication of FR21C1028I1 publication Critical patent/FR21C1028I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
FR21C1028C 2002-10-17 2021-07-07 Anticorps monoclonaux humains contre le cd20 pour le traitement de la sclérose en plaques Active FR21C1028I1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41916302P 2002-10-17 2002-10-17
US46002803P 2003-04-02 2003-04-02
PCT/US2003/033057 WO2004035607A2 (fr) 2002-10-17 2003-10-17 Anticorps monoclonaux humains anti-cd20
EP03809145A EP1558648B1 (fr) 2002-10-17 2003-10-17 Anticorps monoclonaux humains anti-cd20
EP10013085.5A EP2316856B1 (fr) 2002-10-17 2003-10-17 Anticorps monoclonaux humains contre le CD20

Publications (1)

Publication Number Publication Date
FR21C1028I1 true FR21C1028I1 (fr) 2021-08-27

Family

ID=32110219

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1028C Active FR21C1028I1 (fr) 2002-10-17 2021-07-07 Anticorps monoclonaux humains contre le cd20 pour le traitement de la sclérose en plaques

Country Status (25)

Country Link
US (3) US8529902B2 (fr)
EP (4) EP3284753B1 (fr)
JP (3) JP4662473B2 (fr)
KR (7) KR101348472B1 (fr)
CN (3) CN101928344B (fr)
AT (1) ATE540978T1 (fr)
AU (1) AU2003301445A1 (fr)
BR (1) BRPI0315295C1 (fr)
CA (2) CA2502552C (fr)
CY (2) CY1112750T1 (fr)
DK (2) DK3284753T3 (fr)
EA (2) EA201492217A1 (fr)
ES (3) ES2744275T3 (fr)
FR (1) FR21C1028I1 (fr)
HK (1) HK1077590A1 (fr)
HU (2) HUE046695T2 (fr)
IL (2) IL167851A (fr)
LT (2) LT3284753T (fr)
LU (1) LU92041I2 (fr)
MX (1) MXPA05004022A (fr)
NZ (2) NZ568769A (fr)
PL (2) PL218660B1 (fr)
PT (2) PT1558648E (fr)
SI (1) SI1558648T1 (fr)
WO (1) WO2004035607A2 (fr)

Families Citing this family (437)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
ATE196606T1 (de) * 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
HU228180B1 (hu) * 1998-08-11 2013-01-28 Biogen Idec Inc Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára
DK1616572T3 (da) * 1998-11-09 2010-12-06 Biogen Idec Inc Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi
MXPA01004649A (es) * 1998-11-09 2002-05-06 Idec Pharma Corp Tratamiento con anticuerpo quimerico anti-cd20 para pacientes que reciben transplantes de medula osea o celulas madre de sangre periferica.
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
SI1572744T1 (sl) 2002-12-16 2010-09-30 Genentech Inc Imunoglobulinske variante in njihove uporabe
AU2004252067B2 (en) * 2003-05-09 2012-04-12 Duke University CD20-specific antibodies and methods of employing same
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US20050053602A1 (en) * 2003-08-29 2005-03-10 Genentech, Inc. Therapy of ocular disorders
TR201809892T4 (tr) 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
FR2867982B1 (fr) * 2004-03-26 2007-07-20 Jean Marie Andrieu Procede pour amplifier l'activite de vaccins therapeutiques
BRPI0509412A (pt) * 2004-04-16 2007-09-04 Genentech Inc método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado
BRPI0509419A (pt) * 2004-04-16 2007-09-04 Genentech Inc método de ensaio imunossorvente ligado por enzimas, anticorpos, hibridoma e kit de imunoensaio
WO2005113003A2 (fr) * 2004-04-16 2005-12-01 Genentech, Inc. Methode permettant d'augmenter l'appauvrissement des lymphocytes b
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US20050271658A1 (en) * 2004-05-05 2005-12-08 Genentech, Inc. Preventing autoimmune disease
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AR049200A1 (es) * 2004-06-04 2006-07-05 Genentech Inc Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20
NZ551974A (en) * 2004-07-02 2010-01-29 Inst Medical W & E Hall Alpha-helical minetics
WO2006085967A2 (fr) * 2004-07-09 2006-08-17 Xencor, Inc. Anticorps monoclonaux optimises anti-cd20 a variants fc
CN101001873B (zh) 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Fc区变体
EP1812060A2 (fr) * 2004-10-05 2007-08-01 Genentech, Inc. Methode de traitement de l'angeite
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
US10206998B2 (en) 2005-01-12 2019-02-19 Proteonova, Inc. Modular targeted therapeutic agents and methods of making same
EP1846432A4 (fr) * 2005-01-12 2008-11-19 Proteonova Inc Procédé de fabrication d'agents thérapeutiques ciblés
SI2567976T1 (sl) * 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
JP5224707B2 (ja) * 2005-04-28 2013-07-03 持田製薬株式会社 抗血小板膜糖蛋白質ｖｉモノクローナル抗体
ES2864039T3 (es) 2005-05-20 2021-10-13 Lonza Biologics Plc Expresión de alto nivel de un anticuerpo recombinante en una célula huésped de mamífero
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
BRPI0611220A2 (pt) * 2005-06-02 2010-08-24 Astrazeneca Ab anticorpos direcionados para cd20 e usos dos mesmos
JP2009501913A (ja) 2005-07-21 2009-01-22 ゲンマブ エー／エス Ｆｃ受容体と結合する抗体原薬に関する効力アッセイ
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
EP1762575A1 (fr) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification d' antigènes associés aux tumeurs pour diagnose et thérapie
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
KR20140057635A (ko) 2006-03-15 2014-05-13 알렉시온 파마슈티칼스, 인코포레이티드 보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
TWI390034B (zh) * 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
EP2046383B1 (fr) 2006-07-04 2014-11-19 Genmab A/S Molécules de liaison à cd20 pour le traitement de copd
JP5476122B2 (ja) * 2006-09-26 2014-04-23 ゲンマブ エー／エス Ｃｄ３８発現腫瘍の併用処置法
MX2009003306A (es) * 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
EP2120915B1 (fr) 2007-01-22 2011-09-28 Genentech, Inc. Précipitation de polyélectrolyte et purification de protéines
EP1970384A1 (fr) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Anticorps monoclonaux pour le traitement du cancer
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
EP1997832A1 (fr) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
EP2468301A1 (fr) 2007-05-29 2012-06-27 Novartis AG Nouvelles indications pour une thérapie anti-IL-1-bêta
US20100267934A1 (en) 2007-05-31 2010-10-21 Genmab A/S Stable igg4 antibodies
US9322035B2 (en) 2007-05-31 2016-04-26 Genmab A/S Recombinant IgG4 monovalent antibodies
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
ES2527297T3 (es) * 2007-07-31 2015-01-22 Regeneron Pharmaceuticals, Inc. Anticuerpos humanos para CD20 humano y método para utilizar los mismos
JP5209723B2 (ja) * 2007-09-05 2013-06-12 エフ．ホフマン−ラ ロシュ アーゲー Ｉ型及びｉｉ型抗ｃｄ２０抗体による組合せ治療
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
EP2200631A1 (fr) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combinaison d'agents d'inhibition de blys et d'agents anti-cd 20 pour le traitement d'une maladie auto-immune
US20110091473A1 (en) * 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
PL2840090T3 (pl) 2007-10-30 2018-07-31 Genentech, Inc. Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
US20090169550A1 (en) * 2007-12-21 2009-07-02 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (fr) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique
PT2268310T (pt) * 2008-03-25 2016-08-23 Roche Glycart Ag Uso de um anticorpo anti-cd20 do tipo ii com citotoxicidade celular acrescida dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não-hodgkin
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
US20090269339A1 (en) * 2008-04-29 2009-10-29 Genentech, Inc. Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
WO2010014784A2 (fr) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec divers régimes thérapeutiques pour un traitement synergétique de maladies prolifératives
SI2848625T1 (sl) 2008-08-14 2019-11-29 Genentech Inc Postopki za odstranjevanje kontaminanta z uporabo ionskoizmenjevalne membranske kromatografije z izpodrinjenjem nativnega proteina
EP2334323A2 (fr) 2008-09-10 2011-06-22 F. Hoffmann-La Roche AG Compositions et procédés permettant d éviter la dégradation oxydative des protéines
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
EP2166021A1 (fr) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Anticorps monoclonaux pour le traitement du cancer
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
EP2373687B1 (fr) 2008-12-03 2016-10-26 Genmab A/S Variants d'anticorps igg4 comportant des modifications dans la région constante
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
CA2744670C (fr) * 2009-01-06 2018-05-15 Ziad Mallat Agent de depletion des lymphocytes b pour le traitement de l'atherosclerose
CN102355907A (zh) * 2009-01-16 2012-02-15 葛兰素史密斯克莱有限责任公司 用苯达莫司汀和抗cd20抗体的组合治疗癌症
WO2010094499A1 (fr) 2009-02-20 2010-08-26 Ganymed Pharmaceuticals Ag Methodes et compositions de diagnostic et de traitement du cancer
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
EP2456790A1 (fr) 2009-07-20 2012-05-30 Bristol-Myers Squibb Company Combinaison d un anticorps anti-ctla-4 avec divers régimes de traitement pour le traitement synergique de maladies prolifératives
JP2013501741A (ja) 2009-08-14 2013-01-17 ロシュ グリクアート アーゲー アフコシル化ｃｄ２０抗体とフルダラビン及び／又はミトキサントロンの併用療法
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
MX353186B (es) 2009-09-03 2018-01-05 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US20110070227A1 (en) * 2009-09-18 2011-03-24 Anna-Marie Novotney-Barry Treatment of Autoimmune and Inflammatory Diseases
EP2496604B1 (fr) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Anticorps contre cd20 canine
CN102741289B (zh) 2009-11-11 2016-08-03 加尼梅德药物公司 密蛋白6(cldn6)特异性的抗体
EP2322555A1 (fr) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Anticorps spécifiques pour claudin 6 (CLDN6)
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011100398A1 (fr) * 2010-02-10 2011-08-18 Immunogen, Inc. Anticorps anti-cd20 et leurs utilisations
MX341687B (es) * 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
ES2722201T3 (es) 2010-03-22 2019-08-08 Hoffmann La Roche Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas
EP2371864A1 (fr) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Anticorps monoclonaux pour le traitement du cancer
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011131746A2 (fr) 2010-04-20 2011-10-27 Genmab A/S Protéines contenant des anticorps fc hétérodimères et leurs procédés de production
ES2617777T5 (es) † 2010-04-23 2022-10-13 Hoffmann La Roche Producción de proteínas heteromultiméricas
CA2795544A1 (fr) 2010-04-27 2011-11-03 Roche Glycart Ag Polytherapie d'un anticorps anti-cd20 afucosyle et d'un inhibiteur de mtor
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
US9403855B2 (en) 2010-05-10 2016-08-02 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
CN103154035B (zh) 2010-05-27 2017-05-10 根马布股份公司 针对her2的单克隆抗体
JP6093696B2 (ja) 2010-06-09 2017-03-08 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体
MY184736A (en) 2010-06-24 2021-04-20 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
EP2404936A1 (fr) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
BR112013002535A2 (pt) 2010-08-03 2019-09-24 Hoffmann La Roche biomarcadores de leucemia linfocítica crônica (cll)
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AR082693A1 (es) 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
CA3162352A1 (fr) 2010-10-01 2012-04-05 Modernatx, Inc. Nucleosides, nucleotides et acides nucleiques modifies, et utilisations connexes
RU2013126477A (ru) 2010-11-08 2014-12-20 Дженентек, Инк. Вводимые подкожно антитела против рецептора il-6
EP4303236A3 (fr) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Agent thérapeutique inducteur de cytotoxicité
JP6157045B2 (ja) * 2010-12-06 2017-07-05 公益財団法人がん研究会 Ｃｄ２０認識モノクローナル抗体、ハイブリドーマ、ｃｄ２０の検出方法および判定方法
KR20130088170A (ko) 2010-12-16 2013-08-07 로슈 글리카트 아게 비푸코실화 ｃｄ20 항체와 ｍｄｍ2 저해제와의 조합 치료
JP2014506258A (ja) * 2011-01-10 2014-03-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 新規使用
EP2680884B1 (fr) 2011-02-28 2018-01-17 F. Hoffmann-La Roche AG Marqueurs biologiques et procédés de prédiction de réponse à des antagonistes de lymphocytes b
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
JP6177231B2 (ja) 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体
JP2014514314A (ja) 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
PL3026064T3 (pl) 2011-05-13 2019-05-31 Ganymed Pharmaceuticals Gmbh Przeciwciała do leczenia nowotworu z ekspresją klaudyny 6
RS58765B1 (sr) 2011-05-21 2019-06-28 Macrogenics Inc Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
EP2537933A1 (fr) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US10323081B2 (en) 2011-07-06 2019-06-18 Genmag A/S Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
BR112013033944A2 (pt) 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
CN102875678B (zh) * 2011-07-13 2014-08-06 无锡天演生物技术有限公司 全人源抗人cd20单抗分子及其应用
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2612935T3 (es) * 2011-09-19 2017-05-19 Kymab Limited Anticuerpos, dominios variables y cadenas adaptados para su uso en seres humanos
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AU2012328819B2 (en) 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
SI2771364T1 (sl) 2011-10-27 2019-10-30 Genmab As Produkcija heterodimernih proteinov
CA2853230C (fr) 2011-10-31 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Molecule de liaison a un antigene a conjugaison regulee entre une chaine lourde et une chaine legere
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
EP2791160B1 (fr) 2011-12-16 2022-03-02 ModernaTX, Inc. Compositions de mrna modifiés
BR112014015101A8 (pt) 2011-12-22 2021-06-08 Genentech Inc métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos
US20130243750A1 (en) 2012-01-31 2013-09-19 Genentech, Inc. Anti-ige antibodies and methods using same
CN102585000B (zh) * 2012-02-22 2013-05-29 尉军 一种肿瘤标志物cd25自身抗体及应用
US20150110779A1 (en) 2012-03-15 2015-04-23 Bristol-Myers Squibb Company Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243946A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
ES2729729T3 (es) 2012-05-07 2019-11-05 Astellas Pharma Inc Anticuerpos que se unen a PLAC1 y bloquean la interacción entre PLAC1 y FGF7
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2013169971A1 (fr) 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anticorps antitumoraux à titre de biomarqueurs prédictifs ou pronostiques de l'efficacité et de la survie chez les patients traités à l'ipilimumab
CA2873646C (fr) 2012-05-18 2022-04-26 Genentech, Inc. Formulations d'anticorps monoclonal a concentration elevee
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
EP3725810B1 (fr) 2012-05-23 2022-07-06 Astellas Pharma Inc. Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 pour le traitement du cancer
WO2013174403A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
DK3254695T3 (da) 2012-05-23 2020-11-30 Astellas Pharma Inc Kombinationsterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer
PT2869845T (pt) * 2012-07-06 2019-12-09 Genmab Bv Proteína dimérica com mutações triplas
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
EP3632462A1 (fr) 2012-07-06 2020-04-08 Genmab B.V. Protéine dimérique ayant des mutations triples
CN103588882B (zh) * 2012-08-13 2015-10-28 中国抗体制药有限公司 针对人cd22抗体的抗独特型抗体及其应用
CA2880701A1 (fr) 2012-08-18 2014-02-27 Academia Sinica Sondes permeables aux cellules pour l'identification et l'imagerie de sialidases
AU2013305827A1 (en) 2012-08-21 2015-03-05 Academia Sinica Benzocyclooctyne compounds and uses thereof
US8643360B1 (en) * 2012-09-02 2014-02-04 George S. Cargill, III In-water voltage gradient detector
US9539251B2 (en) 2012-09-07 2017-01-10 Genentech, Inc. Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
ES2773107T3 (es) 2012-10-05 2020-07-09 Kyowa Kirin Co Ltd Composición de proteína heterodimérica
EP4035685A1 (fr) 2012-10-30 2022-08-03 Esperance Pharmaceuticals, Inc. Conjugués anticorps-médicament et procédés d'utilisation
EP3766903A3 (fr) 2012-11-13 2021-02-17 BioNTech SE Anticorps bispecifiques anti claudin xcd3 pour le traitement de maladies cancéreuses exprimant claudine
WO2014075697A1 (fr) 2012-11-13 2014-05-22 Biontech Ag Agents de traitement de maladies cancéreuses exprimant claudine
MX369276B (es) * 2012-11-13 2019-11-04 Biontech Ag Agentes para tratamiento de enfermedades cancerosas que expresan claudina.
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
CN103173412B (zh) * 2012-12-07 2015-04-22 天津三箭生物技术有限公司 小鼠抗人cd20单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
KR20200134340A (ko) 2013-01-10 2020-12-01 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
RS63738B1 (sr) 2013-02-20 2022-12-30 Astellas Pharma Inc Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
CA2906057A1 (fr) 2013-03-13 2014-10-02 Genentech, Inc. Formulations d'anticorps
FR3003171B1 (fr) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
EP2976360B1 (fr) 2013-03-18 2019-11-27 Astellas Pharma Inc. Therapie avec des anticorps contre claudin 18.2 pour le traitement du cancer
CA2908380A1 (fr) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Procedes de traitement du cancer
PL2986312T3 (pl) 2013-04-19 2022-04-19 Cytune Pharma Oparte na cytokinie leczenie z ograniczeniem zespołu przesiąkania naczyniowego
CN103254317B (zh) * 2013-05-08 2014-08-13 浙江大学 一种抗cd20单克隆抗体-海兔毒素偶联物及其制备方法和应用
WO2014210397A1 (fr) 2013-06-26 2014-12-31 Academia Sinica Antigènes rm2 et leur utilisation
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
NZ715896A (en) * 2013-07-05 2022-02-25 Genmab As Humanized or chimeric cd3 antibodies
EP3738612A1 (fr) 2013-07-31 2020-11-18 Biontech AG Diagnostic et traitement du cancer impliquant des cellules souches cancéreuses
WO2015014376A1 (fr) 2013-07-31 2015-02-05 Biontech Ag Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses
EP4269441A3 (fr) 2013-08-08 2024-01-24 Cytune Pharma Domaine sushi de l'il-15 et de l'il-15ralpha basé sur des modulokines
EP3659622A1 (fr) 2013-08-08 2020-06-03 Cytune Pharma Composition pharmaceutique combinée
CN103467605B (zh) * 2013-09-05 2015-02-04 武汉友芝友生物制药有限公司 一种cd3抗原及其制备方法和用途
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (fr) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides codant pour un recepteur de lipoproteines de faible densite
AU2014346852A1 (en) 2013-11-05 2016-06-16 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
MX2016005801A (es) * 2013-11-07 2016-11-29 Ono Pharmaceutical Co Terapia de combinacion de un anticuerpo anti cd20 con un inhibidor de btk.
ES2839087T3 (es) 2013-11-12 2021-07-05 Ogd2 Pharma Anticuerpo derivado de IGG1 humana con actividad pro-apoptótica
RU2016128726A (ru) 2013-12-17 2018-01-23 Дженентек, Инк. Способы лечения злокачественных опухолей с использованием антагонистов связывания по оси pd-1 и антитела против cd20
WO2015109180A2 (fr) 2014-01-16 2015-07-23 Academia Sinica Compositions et méthodes pour traiter et détecter des cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
EP2910645A1 (fr) 2014-02-25 2015-08-26 STRATIFYER Molecular Pathology GmbH Procédés et compositions pour la prédiction de l'efficacité thérapeutique de traitements du cancer et le pronostic du cancer lors d'un traitement à base d'anticorps
EP2915569A1 (fr) 2014-03-03 2015-09-09 Cytune Pharma Procédé de purification de conjugués à base Il -15/IL-15Ralpha
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CN103880957B (zh) * 2014-03-27 2016-01-20 安徽大学 抗cd20抗原的抗体l1h1及其应用
JP6562942B2 (ja) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 反応性標識化合物およびその使用
CN103880958B (zh) * 2014-03-27 2016-01-20 安徽大学 抗cd20抗原的抗体l4h6及其应用
NZ724710A (en) 2014-04-07 2024-02-23 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
EP3134113A4 (fr) 2014-04-25 2017-11-29 University of Florida Research Foundation, Inc. Méthodes permettant qu'un sujet reçoive des doses multiples de virus adéno-associé recombinant
HUE063273T2 (hu) 2014-05-06 2024-01-28 Hoffmann La Roche Heteromultimer fehérjék elõállítása emlõssejtek felhasználásával
TW201623333A (zh) 2014-05-13 2016-07-01 Chugai Pharmaceutical Co Ltd 對具有免疫抑制機能之細胞的ｔ細胞重定向抗原結合分子
AU2015267047A1 (en) 2014-05-27 2017-01-05 Academia Sinica Anti-CD20 glycoantibodies and uses thereof
CA2950440A1 (fr) 2014-05-27 2015-12-03 Academia Sinica Glycoanticorps anti-her2 et leurs utilisations
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
TWI654202B (zh) 2014-05-27 2019-03-21 中央研究院 增進抗體功效之通用糖型之組合物及方法
AU2015267044A1 (en) 2014-05-28 2016-12-15 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
CA2960712A1 (fr) 2014-09-08 2016-03-17 Academia Sinica Activation des cellules inkt humaines par des glycolipides
BR112017004393A2 (pt) 2014-09-15 2018-02-27 Genentech Inc formulações de anticorpo
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016057898A1 (fr) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Traitement du cancer par agoniste(s) du tlr9 avec des inhibiteurs du point de contrôle
DK3221359T3 (da) 2014-11-17 2020-06-22 Regeneron Pharma Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
JP2017537927A (ja) 2014-12-04 2017-12-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用
DK3233907T3 (da) 2014-12-19 2021-06-07 Genmab As Bispecifikke heterodimeriske proteiner hos gnavere
EP3242682A1 (fr) * 2015-01-08 2017-11-15 Genmab A/S Anticorps bispécifiques dirigés contre cd3 et cd20
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
WO2016118191A1 (fr) 2015-01-24 2016-07-28 Academia Sinica Nouveaux composés conjugués de glycane et leurs méthodes d'utilisation
EP3250588A1 (fr) 2015-01-29 2017-12-06 Board of Trustees of Michigan State University Polypeptides cryptiques et leurs utilisations
KR20220018081A (ko) * 2015-03-04 2022-02-14 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
CA2981068C (fr) 2015-03-26 2021-12-14 Women & Infants Hospital Of Rhode Island Therapie contre les affections malignes comprenant l'inhibition de la proteine secretee de l'epididyme humain e4 et inhibiteurs des points de controle immunitaires
WO2016165762A1 (fr) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Conjugués de médicaments comprenant des anticorps contre la claudine 18.2
WO2016165765A1 (fr) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer
CN107529739B (zh) * 2015-04-30 2021-01-08 株式会社特殊免疫研究所 表达人特定分子和人Fcγ受体家族的转基因非人动物
US20160346387A1 (en) 2015-05-11 2016-12-01 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2016183183A1 (fr) 2015-05-11 2016-11-17 The Johns Hopkins University Anticorps auto-immuns destinés à être utilisés pour inhiber la croissance de cellules cancéreuses
US10881733B2 (en) 2015-05-22 2021-01-05 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
AU2016271475A1 (en) 2015-06-03 2017-12-21 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
EP3108897A1 (fr) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Anticorps contre le csf-1r humain permettant d'induire une lymphocytose dans les lymphomes ou les leucémies
BR112017024610A2 (pt) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag anticorpos para receptor antitransferrina com afinidade especificada
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CA2989936A1 (fr) 2015-06-29 2017-01-05 Genentech, Inc. Anticorps anti-cd20 de type ii destine a une utilisation dans la transplantation d'organes
PT3313528T (pt) 2015-06-29 2021-09-16 Bristol Myers Squibb Co Regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do cancro
WO2017005649A1 (fr) 2015-07-09 2017-01-12 Genmab A/S Anticorps bispécifiques et multispécifiques et procédé pour l'isolement de ceux-ci
KR20210089270A (ko) 2015-07-16 2021-07-15 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
EP3328896A4 (fr) 2015-07-31 2019-08-07 University of Florida Research Foundation, Inc. Cellules souches hématopoïétiques en thérapie combinatoire comprenant des inhibiteurs de points de contrôle immunitaires contre le cancer
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
JP6889149B2 (ja) 2015-08-13 2021-06-18 アムジエン・インコーポレーテツド 抗原結合タンパク質の荷電深層ろ過
CA2999138C (fr) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Polypeptides de liaison a cd3
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
RU2753390C1 (ru) 2015-10-02 2021-08-13 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела к человеческому cd20/человеческому рецептору трансферрина и способы их применения
CA3001910A1 (fr) * 2015-10-13 2017-04-20 Eureka Therapeutics, Inc. Agents de type anticorps specifiques de l'antigene cd19 humain et leurs utilisations
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
CN115920030A (zh) 2015-12-09 2023-04-07 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于降低抗药物抗体形成
EP3178848A1 (fr) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Anticorps de type ii contre cd20 pour la reduction de la formation des anticorps contre des médicaments
CN105348388B (zh) * 2015-12-11 2018-10-19 安徽大学 抗cd20抗原的抗体l3h3及其应用
KR20180091918A (ko) 2015-12-28 2018-08-16 추가이 세이야쿠 가부시키가이샤 Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
KR20180098625A (ko) 2015-12-30 2018-09-04 제넨테크, 인크. 분해가 감소된 폴리소르베이트를 갖는 제형
JP2019517991A (ja) 2016-03-01 2019-06-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 低減したａｄｃｐを有するオビヌツズマブ及びリツキシマブ変異体
EP3423593A1 (fr) 2016-03-02 2019-01-09 Institut National de la Sante et de la Recherche Medicale (INSERM) Procédés et kits de prédiction du risque de rechute chez des patients souffrant d'un syndrome néphrotique idiopathique
CA3016170A1 (fr) 2016-03-08 2017-09-14 Academia Sinica Procedes de synthese modulaire de n-glycanes et de puces a n-glycanes
WO2017160599A1 (fr) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation d'antagonistes de cd300b pour traiter un sepsis et un choc septique
MX2018010988A (es) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
KR102413037B1 (ko) 2016-03-15 2022-06-23 메르사나 테라퓨틱스, 인코포레이티드 Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법
EP3429618B1 (fr) 2016-03-16 2024-02-21 Amal Therapeutics SA Association d'un modulateur de points de contrôle immunologiques et d'un complexe comprenant un peptide de pénétration cellulaire, un cargo et un agoniste des peptides tlr pour une utilisation en médecine
WO2017182608A1 (fr) 2016-04-22 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions vaccinales pour le traitement des malignités des cellules b
US20190298824A1 (en) 2016-05-04 2019-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Albumin-binding immunomodulatory compositions and methods of use thereof
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
US11052148B2 (en) 2016-05-30 2021-07-06 Geo Vax, Inc. Compositions and methods for generating an immune response to hepatitis B virus
EP3252078A1 (fr) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Anticorps de type ii contre cd20 et anticorps bispecifique contre cd20/cd3 pour traitement de cancer
WO2017218515A1 (fr) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anticorps anti-c5 et leurs utilisations
CN109154600A (zh) * 2016-06-16 2019-01-04 豪夫迈·罗氏有限公司 用于确定cdc诱导抗体的测定法和方法
MX2019000252A (es) 2016-06-30 2019-10-09 Oncorus Inc Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos.
CN106267406B (zh) * 2016-07-01 2019-02-01 翁炳焕 艾滋病血液净化器
US11649289B2 (en) 2016-08-04 2023-05-16 Glaxosmithkline Intellectual Property Development Limited Anti-ICOS and anti-PD-1 antibody combination therapy
EP3500594A4 (fr) 2016-08-22 2020-03-11 Cho Pharma Inc. Anticorps, fragments de liaison, et procédés d'utilisation
US11414495B2 (en) * 2016-09-01 2022-08-16 Tiga Tx, Inc. CD20 antibodies
CA3031170A1 (fr) 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprenant un peptide de penetration cellulaire, un multi-epitope et un agoniste des peptides tlr pour le traitement du cancer
WO2018054484A1 (fr) 2016-09-23 2018-03-29 Biontech Ag Anticorps trivalents bispécifiques se liant à claudine 6 ou claudin18.2 et cd3 pour le traitement de maladies cancéreuses exprimant la claudine
WO2018083126A1 (fr) 2016-11-01 2018-05-11 Genmab B.V. Variants polypeptidiques et ses utilisations
AU2017363337B2 (en) 2016-11-23 2021-07-01 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018099539A1 (fr) 2016-11-29 2018-06-07 Horst Lindhofer Combinaison d'anticorps multifonctionnels de redirection de lymphocytes (t) avec des modulateurs de point de contrôle immunitaires et leurs utilisations
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3045243A1 (fr) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Polytherapie
US20200003785A1 (en) 2016-12-01 2020-01-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of anti-uchl1 igg plasma concentration for diagnosing idiopathic steroid sensitive nephrotic syndrome
JP2020500878A (ja) 2016-12-01 2020-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 併用療法
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018114754A1 (fr) 2016-12-19 2018-06-28 F. Hoffmann-La Roche Ag Polythérapie avec des agonistes de 4-1bb (cd137) ciblés
ES2847973T3 (es) 2016-12-20 2021-08-04 Hoffmann La Roche Politerapia de anticuerpos biespecíficos anti-CD20/anti-CD3 y agonistas de 4-1BB (CD137)
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
US11229668B2 (en) 2017-02-07 2022-01-25 Nantcell, Inc. Maximizing T-cell memory and compositions and methods therefor
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
BR112019015900A2 (pt) 2017-02-10 2020-04-07 Genmab B.V. polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
WO2018167780A1 (fr) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Méthodes de diagnostic et de traitement du cancer
WO2018167778A1 (fr) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Procédés de diagnostic et de pronostic du cancer
EP3600416B1 (fr) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libéré à l'aide d'un dispositif ingérable
US20200270359A1 (en) 2017-03-31 2020-08-27 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
JP7090347B2 (ja) 2017-05-12 2022-06-24 ハープーン セラピューティクス，インク． メソテリン結合タンパク質
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
KR20200014304A (ko) 2017-06-02 2020-02-10 에프. 호프만-라 로슈 아게 암의 치료를 위한 제ii형 항-cd20 항체 및 항-cd20/항-cd3 이중특이적 항체
BR112019024291A2 (pt) 2017-06-09 2020-07-28 Providence Health & Services-Oregon utilização de cd39 e de cd103 para a identificação de células t tumorais humanas reativas para o tratamento do câncer
CN107446046A (zh) * 2017-07-05 2017-12-08 无锡傲锐东源生物科技有限公司 抗cd20蛋白单克隆抗体及其用途
CN110869391A (zh) 2017-07-26 2020-03-06 豪夫迈·罗氏有限公司 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法
WO2019036855A1 (fr) 2017-08-21 2019-02-28 Adagene Inc. Molécules anti-cd137 et leur utilisation
WO2019048040A1 (fr) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh Anticorps utiles dans le diagnostic du cancer
AU2018346955A1 (en) 2017-10-13 2020-04-30 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
WO2019077123A1 (fr) 2017-10-20 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et kits pour identifier si un sujet est atteint ou risque d'être atteint d'une myopathie auto-immune
EP3717021A1 (fr) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Conjugués anticorps-pyrrolobenzodiazépine
CN111212660A (zh) 2017-12-14 2020-05-29 豪夫迈·罗氏有限公司 Cea cd3双特异性抗体和pd-1轴结合拮抗剂在治疗癌症的剂量方案中的用途
WO2019126691A1 (fr) 2017-12-21 2019-06-27 Mersana Therapeutics, Inc. Conjugués anticorps-pyrrolobenzodiazépine
EP3731850A4 (fr) 2017-12-29 2021-12-01 Oncorus, Inc. Administration par un virus oncolytique de polypeptides thérapeutiques
EP3743440A1 (fr) 2018-01-24 2020-12-02 Genmab B.V. Variants polypeptidiques et leurs utilisations
WO2019148445A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation
CN112218658A (zh) 2018-03-12 2021-01-12 国家健康科学研究所 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
JP7159332B2 (ja) 2018-03-13 2022-10-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ４－１ｂｂアゴニストと抗ｃｄ２０抗体の治療的組み合わせ
WO2019175125A1 (fr) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Polythérapie avec des agonistes de 4-1 bb (cd137) ciblés
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
US20210253614A1 (en) 2018-05-31 2021-08-19 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
JP2021527651A (ja) 2018-06-15 2021-10-14 ミナ セラピューティクス リミテッド Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
CN112513074A (zh) 2018-06-22 2021-03-16 健玛保 生产两种或更多种不同抗体的受控混合物的方法
EP3810194A1 (fr) 2018-06-22 2021-04-28 Genmab Holding B.V. Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci
KR20210031679A (ko) * 2018-07-09 2021-03-22 밀레니엄 파머슈티컬스 인코퍼레이티드 수모-활성화 효소 저해제 및 항-cd20 항체의 투여
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
AU2019331024A1 (en) 2018-08-31 2021-03-18 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
WO2020048942A1 (fr) 2018-09-04 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques visant à améliorer les réponses immunitaires dépendantes des lymphocytes t cytotoxiques
EP3852788A1 (fr) 2018-09-17 2021-07-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Récepteurs antigéniques chimériques bicistroniques ciblant cd19 et cd20 et leurs utilisations
US20220073638A1 (en) 2018-09-19 2022-03-10 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
WO2020070053A1 (fr) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs de formation de granules de stress pour cibler la régulation de réponses immunitaires
SG11202103100SA (en) 2018-10-04 2021-04-29 Genmab Holding B V Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
WO2020080715A1 (fr) 2018-10-15 2020-04-23 연세대학교 산학협력단 Anticorps à productivité améliorée et procédé de production correspondant
MX2021004732A (es) * 2018-10-26 2021-06-04 Teneobio Inc Anticuerpos de cadena pesada que se unen a cd38.
EP3873534A1 (fr) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Conjugués anticorps-médicament modifiés par une cystéine avec des lieurs contenant des peptides
WO2020106754A1 (fr) 2018-11-19 2020-05-28 Progenity, Inc. Méthodes et dispositifs pour traiter une maladie à l'aide d'agents biothérapeutiques
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
WO2020109355A1 (fr) 2018-11-28 2020-06-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et kit de dosage du potentiel lytique de cellules effectrices immunitaires
AU2018451747A1 (en) 2018-12-06 2021-06-17 F. Hoffmann-La Roche Ag Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
US20220018835A1 (en) 2018-12-07 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
EP3894401A2 (fr) 2018-12-11 2021-10-20 Theravance Biopharma R&D IP, LLC Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
WO2020127059A1 (fr) 2018-12-17 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de sulconazole en tant qu'inhibiteur de la furine
JP2022517029A (ja) 2019-01-15 2022-03-03 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用
WO2020169472A2 (fr) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés d'induction de changements phénotypiques dans des macrophages
MX2021012032A (es) 2019-04-01 2021-11-03 Genentech Inc Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
WO2020201362A2 (fr) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de prédiction et de prévention du cancer chez des patients ayant des lésions prémalignes
WO2020208060A1 (fr) 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs de sk2 en association avec une thérapie de blocage de point de contrôle immunitaire pour le traitement du cancer
WO2020212484A1 (fr) 2019-04-17 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions de traitement de troubles dépendants de il-1beta mediés par inflamasome nlrp3
BR112021022815A2 (pt) 2019-05-14 2021-12-28 Genentech Inc Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
JP2022539248A (ja) 2019-07-02 2022-09-07 フレッド ハッチンソン キャンサー リサーチ センター 組換えａｄ３５ベクター及び関連遺伝子治療改善
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
WO2021024020A1 (fr) 2019-08-06 2021-02-11 Astellas Pharma Inc. Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer
WO2021041678A1 (fr) * 2019-08-30 2021-03-04 Qilu Puget Sound Biotherapeutics Corporation Anticorps anti-cd20, anticorps anti-cd37 et leurs mélanges
ES2957112T3 (es) 2019-09-11 2024-01-11 Novartis Ag Tratamiento del RMS mediante cambio de terapia
CA3152192A1 (fr) 2019-09-11 2021-03-18 Novartis Ag Gestion d'etats autres que la sclerose en plaques chez des patients traites par l'ofatumumab
AU2020345913A1 (en) 2019-09-12 2022-02-24 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2021058091A1 (fr) 2019-09-24 2021-04-01 Biontech Rna Pharmaceuticals Gmbh Traitement impliquant un anticorps thérapeutique et l'interleukine-2 (il2)
EP3800201A1 (fr) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Stimulation cd28h améliorant des activités de destruction de cellules nk
EP4037710A1 (fr) 2019-10-04 2022-08-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes et composition pharmaceutique pour le traitement du cancer de l'ovaire, du cancer du sein ou du cancer du pancréas
BR112022007216A2 (pt) 2019-10-18 2022-08-23 Genentech Inc Métodos para tratamento de linfoma difuso, kit e imunoconjugado
EP4055046A1 (fr) 2019-11-06 2022-09-14 Genmab B.V. Combinaisons de variants d'anticorps et leurs utilisations
CN114728941A (zh) 2019-11-22 2022-07-08 施万生物制药研发Ip有限责任公司 作为alk5抑制剂的经取代的1,5-萘啶或喹啉
CN111100204B (zh) * 2019-11-26 2022-03-11 山东立菲生物产业有限公司 靶向cd20的抗体、其制备方法和应用
WO2021119482A1 (fr) 2019-12-13 2021-06-17 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal
WO2021165488A1 (fr) 2020-02-21 2021-08-26 Genmab B.V. Procédés de quantification de glycoprotéines
US11673879B2 (en) 2020-03-31 2023-06-13 Theravance Biopharma R&D Ip, Llc Substituted pyrimidines and methods of use
AU2021253674A1 (en) 2020-04-09 2022-11-03 Novartis Ag Ofatumumab for treating MS while maintaining serum IgG
US20230159586A1 (en) 2020-04-21 2023-05-25 University Of Rochester Inhibitors of human epididymus protein 4
MX2022013065A (es) 2020-04-22 2022-12-08 Iovance Biotherapeutics Inc Sistemas y metodos para coordinar la manufactura de celulas para inmunoterapia especifica de acuerdo al paciente.
CA3175530A1 (fr) 2020-04-24 2021-10-28 Genentech, Inc. Procedes d'utilisation d'immunoconjugues anti-cd79b
BR112022022730A2 (pt) 2020-05-08 2023-02-14 Genmab As Método para tratar um linfoma não hodgkin de células b em um indivíduo humano
US20230279116A1 (en) 2020-06-03 2023-09-07 Mv Biotherapeutics Sa Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
TW202214623A (zh) 2020-06-10 2022-04-16 美商施萬生物製藥研發 Ip有限責任公司 結晶型alk5抑制劑及其用途
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
JP2023532768A (ja) 2020-07-07 2023-07-31 バイオエヌテック エスエー Ｈｐｖ陽性癌の治療用ｒｎａ
CA3184940A1 (fr) 2020-07-07 2022-01-13 Jennifer Donglan WU Anticorps mic et agents de liaison et leurs procedes d'utilisation
US20230295146A1 (en) 2020-07-24 2023-09-21 The University Of Rochester Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
CN112062855A (zh) * 2020-08-26 2020-12-11 康诺亚生物医药科技（成都）有限公司 一种含有衔接器的药物治疗剂的开发和应用
WO2022043415A1 (fr) 2020-08-27 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de détection de la présence d'auto-anticorps spécifiques à un pemphigus dans un échantillon
IL301086A (en) 2020-09-10 2023-05-01 Genmab As Bispecific antibody against CD3 and CD20 in combination therapy for the treatment of follicular lymphoma
WO2022053657A1 (fr) 2020-09-10 2022-03-17 Genmab A/S Anticorps bispécifique contre cd3 et cd20 en polythérapie de traitement de lymphome diffus à grandes cellules b
KR20230066391A (ko) 2020-09-10 2023-05-15 젠맵 에이/에스 여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
CA3192251A1 (fr) 2020-09-10 2022-03-17 Genmab A/S Anticorps bispecifique contre cd3 et cd20 en polytherapie pour le traitement un lymphome diffus a grandes cellules b
EP4210745A1 (fr) 2020-09-10 2023-07-19 Genmab A/S Anticorps bispécifique anti-cd3 et anti-cd20 en polythérapie pour traiter un lymphome diffus à grandes cellules b
CA3190349A1 (fr) 2020-09-10 2022-03-17 Brian Elliott Anticorps bispecifiques contre cd3 et cd20 de traitement de la leucemie lymphoide chronique
US20230399403A1 (en) 2020-11-11 2023-12-14 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2022130206A1 (fr) 2020-12-16 2022-06-23 Pfizer Inc. POLYTHÉRAPIES À INHIBITEURS DE TGFβR1
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Programme de traitement faisant intervenir des protéines cytokines
WO2022135667A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Arn thérapeutique pour le traitement du cancer
CA3207090A1 (fr) 2021-01-06 2022-07-14 F. Hoffmann-La Roche Ag Polytherapie utilisant un anticorps bispecifique pd1-lag3 et un anticorps bispecifique de lymphocyte t cd20
JP2024511970A (ja) 2021-03-15 2024-03-18 ジェネンテック， インコーポレイテッド ループス腎炎の治療の組成物及び方法
WO2022204282A1 (fr) 2021-03-24 2022-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs antigéniques chimériques bicistroniques conçus pour réduire la recombinaison rétrovirale et leurs utilisations
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
AU2022244125A1 (en) 2021-03-26 2023-10-19 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
CN117279664A (zh) 2021-04-10 2023-12-22 普方生物制药美国公司 Folr1结合剂、其偶联物及其使用方法
KR20230170923A (ko) 2021-04-14 2023-12-19 노파르티스 아게 아시아인 환자들에서 ms 치료용 오파투무맙
EP4326768A1 (fr) 2021-04-23 2024-02-28 Profoundbio Us Co. Anticorps anti-cd70, leurs conjugués et leurs procédés d'utilisation
EP4329777A1 (fr) 2021-04-28 2024-03-06 MiNA Therapeutics Limited Polythérapies comprenant c/ebp alpha arnsa
WO2022228706A1 (fr) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosage pour le traitement avec un anticorps bispécifique anti-cd20/anti-cd3
KR20240005691A (ko) 2021-04-30 2024-01-12 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
AU2022270697A1 (en) 2021-05-07 2023-10-19 Viela Bio, Inc. Use of an anti-cd19 antibody to treat myasthenia gravis
CN117396232A (zh) 2021-05-12 2024-01-12 基因泰克公司 使用抗cd79b免疫缀合物治疗弥漫性大b细胞淋巴瘤的方法
WO2022251359A1 (fr) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Inhibiteurs bicycliques de l'alk5 et procédés d'utilisation
EP4347647A1 (fr) 2021-06-01 2024-04-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Utilisation d'agents de déplétion de lymphocytes b pour le traitement d'une cardiopathie rhumatismale
KR20240049794A (ko) 2021-06-07 2024-04-17 프로비던스 헬스 앤드 서비시즈 - 오레곤 Cxcr5, pd-1, 및 icos 발현 종양 반응성 cd4 t 세포 및 그의 용도
WO2022262959A1 (fr) 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Agents de liaison bispécifiques se liant à cldn18.2 et cd3
EP4355779A1 (fr) 2021-06-17 2024-04-24 Glaxosmithkline Intellectual Property Limited Anticorps anti-baff destinés à être utilisés dans une méthode de traitement d'une infection par sars-cov-2 à séquelles de covid prolongées et/ou post-aiguës (pasc)
EP4367269A1 (fr) 2021-07-05 2024-05-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Signatures génétiques pour prédire la durée de survie chez les patients souffrant d'un carcinome des cellules rénales
EP4370552A1 (fr) 2021-07-13 2024-05-22 BioNTech SE Agents de liaison multispécifiques contre cd40 et cd137 en polythérapie du cancer
KR20240046524A (ko) 2021-08-07 2024-04-09 제넨테크, 인크. 미만성 거대 b-세포 림프종을 치료하기 위해 항-cd79b 면역접합체를 사용하는 방법
KR20240046200A (ko) 2021-08-16 2024-04-08 노파르티스 아게 소아 ms 치료를 위한 오파투무맙
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CA3238167A1 (fr) 2021-11-19 2023-05-25 Maria Leia Smith Agents de liaison de gpc3, leurs conjugues et leurs procedes d'utilisation
US20230241211A1 (en) 2022-01-28 2023-08-03 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
US20230303693A1 (en) 2022-01-28 2023-09-28 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
US20230414750A1 (en) 2022-03-23 2023-12-28 Hoffmann-La Roche Inc. Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
WO2023198839A2 (fr) 2022-04-13 2023-10-19 Genmab A/S Anticorps bispécifiques dirigés contre cd3 et cd20
TW202404637A (zh) 2022-04-13 2024-02-01 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
WO2023201369A1 (fr) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Processus d'expansion de til utilisant des combinaisons spécifiques de cytokine et/ou traitement akti
US11932693B2 (en) 2022-05-12 2024-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
CN116162153A (zh) * 2022-09-01 2023-05-26 复旦大学附属中山医院 一种乙肝病毒表面抗原的单克隆抗体及其应用
WO2024052356A1 (fr) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Inhibiteurs de la voie métabolique de céramide pour surmonter la résistance à l'immunothérapie dans le cancer
WO2024094822A1 (fr) 2022-11-02 2024-05-10 Genmab A/S Anticorps bispécifiques dirigés contre cd3 et cd20 pour le traitement du syndrome de richter
WO2024094741A1 (fr) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Polythérapie avec un anticorps bispécifique anti-cd19/anti-cd28
WO2024102734A1 (fr) 2022-11-08 2024-05-16 Genentech, Inc. Compositions et méthodes de traitement du syndrome néphrotique idiopathique de l'enfant

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US6218525B1 (en) * 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
WO1992022645A1 (fr) 1991-06-14 1992-12-23 Genpharm International, Inc. Animaux transgeniques non humains presentant une deficience immunitaire
CA2113113A1 (fr) 1991-07-08 1993-01-21 Simon W. Kantor Copolymere sequence a cristaux liquides thermotropiques
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
DE69233628T2 (de) 1991-07-25 2007-04-26 Biogen Idec Inc., San Diego Rekombinante Antikörper zur humanen Therapie
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE196606T1 (de) * 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6096878A (en) * 1993-05-10 2000-08-01 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
JP2000516594A (ja) 1996-07-26 2000-12-12 スミスクライン・ビーチャム・コーポレイション 免疫細胞介在全身性疾患の改良された治療法
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
WO1999014353A2 (fr) 1997-09-19 1999-03-25 Dana-Farber Cancer Institute, Inc. Regulation a mediation intracorps de reactions immunitaires.
DE69839529D1 (de) 1997-12-24 2008-07-03 Ludwig Inst Cancer Res Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO2000003733A1 (fr) 1998-07-16 2000-01-27 Vincent Marinkovich Methodes et compositions pour traiter le cancer
HU228180B1 (hu) * 1998-08-11 2013-01-28 Biogen Idec Inc Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
DK1616572T3 (da) * 1998-11-09 2010-12-06 Biogen Idec Inc Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi
MXPA01004649A (es) 1998-11-09 2002-05-06 Idec Pharma Corp Tratamiento con anticuerpo quimerico anti-cd20 para pacientes que reciben transplantes de medula osea o celulas madre de sangre periferica.
AU777970C (en) 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
EP1194167B1 (fr) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapie de troubles auto-immuns a l'aide d'anticorps ciblant les cellules b
JP2003528805A (ja) 1999-07-12 2003-09-30 ジェネンテック・インコーポレーテッド Ｃｄ２０に結合するアンタゴニストを用いた異種抗原に対する免疫応答のブロッキング
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
AU784971B2 (en) 1999-08-11 2006-08-10 Biogen Inc. Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies
DE60033530T2 (de) 1999-08-24 2007-10-31 Medarex Inc. Humane antikörper gegen ctla-4 und deren verwendungen
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
IL149500A0 (en) 1999-11-08 2002-11-10 Idec Pharma Corp Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
WO2002004021A1 (fr) 2000-07-12 2002-01-17 Idec Pharmaceuticals Corporation Traitement de malignites des cellules b au moyen d'une combinaison d'anticorps a action depletive sur les cellules b et des applications relatives a l'anticorps de modulation immunitaire
AU2001233277B2 (en) 2000-02-03 2004-06-03 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
EP1125905A1 (fr) 2000-02-16 2001-08-22 Pepscan Systems B.V. Synthèse de segments
JP2003528155A (ja) * 2000-03-24 2003-09-24 カイロン コーポレイション Ｃｄ２０に対する抗体とインターロイキン−２との組み合わせを用いる非ホジキンリンパ腫の治療方法
US20020064823A1 (en) * 2000-03-30 2002-05-30 Welcher Andrew A. CD20/IgE-receptor like molecules and uses thereof
US6896885B2 (en) * 2000-03-31 2005-05-24 Biogen Idec Inc. Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
CN101130078A (zh) 2000-04-25 2008-02-27 拜奥根Idec公司 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗
JP2004512262A (ja) 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
JP2003535907A (ja) 2000-06-22 2003-12-02 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 抗体誘導性細胞溶解を促進し、そして癌を処置するための方法
WO2002007783A2 (fr) 2000-07-20 2002-01-31 Regents Of The University Of Minnesota Immunotoxines radiomarquees
AU8470301A (en) * 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
CA2422076A1 (fr) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Polytherapie pour le traitement de maladies auto-immunes utilisant une combinaison d'anticorps d'immunoregulation/de depletion de cellules b
AU2002213357A1 (en) 2000-10-20 2002-05-06 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
AU3942202A (en) 2000-11-30 2002-06-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
WO2002062946A2 (fr) 2000-12-08 2002-08-15 Duke University Identification de nouveaux membres de la famille de gene ms4a exprimes par des cellules hematopoietiques
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP4463475B2 (ja) 2001-01-31 2010-05-19 バイオジェン アイデック インコーポレイテッド 腫瘍疾患の治療における免疫調節性抗体の使用
WO2002060484A1 (fr) 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Utilisation d'antagonistes cd23 dans le traitement des troubles neoplasiques
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
JP2005500018A (ja) 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
US20090169550A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients

Also Published As

Publication number Publication date
CN1729203A (zh) 2006-02-01
EP3284753A2 (fr) 2018-02-21
LT3284753T (lt) 2020-06-10
CN101928344A (zh) 2010-12-29
NZ568769A (en) 2010-04-30
CA2502552C (fr) 2019-02-12
CA3029035A1 (fr) 2004-04-29
PL218660B1 (pl) 2015-01-30
HUE046695T2 (hu) 2020-03-30
JP5767041B2 (ja) 2015-08-19
EA021644B1 (ru) 2015-08-31
EP1558648A2 (fr) 2005-08-03
EP3284753B1 (fr) 2019-06-05
KR20100050587A (ko) 2010-05-13
US20140093454A1 (en) 2014-04-03
JP2012005485A (ja) 2012-01-12
EP2330130B1 (fr) 2014-08-27
JP2010042002A (ja) 2010-02-25
KR20120128151A (ko) 2012-11-26
EP2316856B1 (fr) 2017-08-09
PT3284753T (pt) 2020-05-04
EA201492217A1 (ru) 2015-06-30
JP2006507844A (ja) 2006-03-09
NZ581541A (en) 2011-07-29
ATE540978T1 (de) 2012-01-15
BRPI0315295C1 (pt) 2021-05-25
IL167851A (en) 2013-12-31
BR0315295A (pt) 2005-08-30
ES2380621T3 (es) 2012-05-16
CY2012019I1 (el) 2015-08-05
KR20050049552A (ko) 2005-05-25
KR20110017020A (ko) 2011-02-18
BRPI0315295B1 (pt) 2018-12-26
EA200500679A1 (ru) 2006-02-24
IL167851A0 (en) 2009-02-11
CN103709250A (zh) 2014-04-09
CY2012019I2 (el) 2015-08-05
US20200317799A1 (en) 2020-10-08
ES2524694T3 (es) 2014-12-11
CN1729203B (zh) 2014-02-19
ES2744275T3 (es) 2020-02-24
EP2330130A1 (fr) 2011-06-08
DK1558648T3 (da) 2012-04-23
BRPI0315295B8 (pt) 2019-08-20
CY1112750T1 (el) 2015-08-05
IL221193A0 (en) 2012-09-24
KR101348472B1 (ko) 2014-01-07
KR20090088973A (ko) 2009-08-20
CN103709250B (zh) 2016-08-10
JP5155968B2 (ja) 2013-03-06
CA2502552A1 (fr) 2004-04-29
KR100944575B1 (ko) 2010-02-25
US20040167319A1 (en) 2004-08-26
EP3284753A3 (fr) 2018-03-14
LTC3284753I2 (fr) 2022-09-12
WO2004035607A8 (fr) 2004-06-17
PL402418A1 (pl) 2013-05-27
KR100932340B1 (ko) 2009-12-16
EP1558648A4 (fr) 2006-02-15
WO2004035607A3 (fr) 2004-08-12
JP4662473B2 (ja) 2011-03-30
EP2316856A1 (fr) 2011-05-04
LU92041I2 (fr) 2014-01-11
WO2004035607A2 (fr) 2004-04-29
LU92041I9 (fr) 2019-01-03
PL376351A1 (en) 2005-12-27
PT1558648E (pt) 2012-04-23
HK1077590A1 (en) 2006-02-17
EP1558648B1 (fr) 2012-01-11
CA3029035C (fr) 2023-03-07
AU2003301445A1 (en) 2004-05-04
LTPA2021514I1 (fr) 2021-07-26
MXPA05004022A (es) 2005-10-05
DK3284753T3 (da) 2021-07-05
PL216630B1 (pl) 2014-04-30
KR20110140142A (ko) 2011-12-30
HUS2100026I1 (hu) 2021-07-28
KR20080090565A (ko) 2008-10-08
US8529902B2 (en) 2013-09-10
CN101928344B (zh) 2014-08-13
SI1558648T1 (sl) 2012-05-31

Similar Documents

Publication Publication Date Title
FR21C1028I1 (fr) Anticorps monoclonaux humains contre le cd20 pour le traitement de la sclérose en plaques
TW200500378A (en) Human antibodies specific for interleukin 15 (IL-15)
ATE531390T1 (de) Interleukin-15-(il-15-)spezifische menschliche antikörper
NO20053417L (no) Humane monoklonale antistoffer mot interleukin 8 (IL-8)
WO2004045512A3 (fr) Anticorps monoclonaux humains contre cd25
WO2004043989A3 (fr) Anticorps monoclonaux humains diriges contre l'heparanase
MXPA05012571A (es) Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
DE60037896D1 (de) Menschliche antikörper gegen her2/neu
AU2003303237A8 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
WO2003059282A3 (fr) Anticorps monoclonaux humains contre cd30
RS20050724A (en) Human antibodies specific for interleukin 15(il-15)